Lineage Cell Therapeutics (LCTX) Misses Q2 EPS by 3c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q2 EPS of ($0.03), $0.03 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $1.4 million .

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Ticketplus files for IPO with shares priced between $13-$15
• Super League Enterprise (SLE) files for 1.07M share offering by selling stockholders